



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|------------------|--|
| <p>(51) International Patent Classification ⁶ : A61K 38/00, 38/32, 38/46</p> | <p>A1</p> | <p>(11) International Publication Number: WO 96/11016 (43) International Publication Date: 18 April 1996 (18.04.96)</p> |
| <p>(21) International Application Number: PCT/US95/12543 (22) International Filing Date: 6 October 1995 (06.10.95) (30) Priority Data: 08/318,994 6 October 1994 (06.10.94) US 08/483,572 7 June 1995 (07.06.95) US (71) Applicants: ALPHA 1 BIOMEDICALS, INC. [US/US]; Two Democracy Center, Suite 1200, 6903 Rockledge Drive, Bethesda, MD 20817-1818 (US). THE GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER [US/US]; 2300 Eye Street, N.W., Washington, DC 20037 (US). (72) Inventors: CROCKFORD, David, R.; 113 Record Street, Frederick, MD 21701 (US). RUBIN, Bruce, K.; 1850 North Signal Hills Drive, Kirkwood, MO 63122 (US). BERMAN, Michael, L.; 8824 Watts Mine Terrace, Potomac, MD 20854 (US). GOLDSTEIN, Allan, L.; 6407 Bradley Boulevard, Bethesda, MD 20817 (US). BAUMAN, Christian; 14355 Georgia Avenue, Silver Spring, MD 20906 (US). KATER, Arnon; 950-25th Street, N.W., 514 South, Washington, DC 20037 (US).</p> | | <p>(74) Agents: REPPER, George, R. et al.; Rothwell, Figg, Ernst & Kurz, 555 13th Street, N.W. #701 East, Washington, DC 20004 (US). (81) Designated States: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p> |
| <p>(54) Title: TREATMENT OF OBSTRUCTIVE AIRWAY DISEASE BY ADMINISTERING THYMOSIN β_4 OR COADMINISTRATION OF THYMOSIN β_4 AND DNase I</p> | | |
| <p>(57) Abstract A method of treating obstructive airway disease (OAD) such as cystic fibrosis involves contacting OAD sputum with a viscoelasticity-reducing amount of Thymosin β_4, or a combination of Thymosin β_4 and DNase I.</p> | | |